Top Federal Health Official Says Marijuana's Legal Status is Inhibiting Research
The U.S. Committee on Appropropriations hosted a hearing September 25th for the Subcommittee on Labor, Health, and Human Services, Education, and Related Agencies. The panelists included Helene Langevin, Director of the National Center for Complementary and Integrative Health (NCCIH), Francis Collins, Director of the National Institute of Health (NIH), and Nora Volkow, Driector of the National Institutes on Drug Abuse. During the hearing the three panels openly agreed that there is a problem with marijuana on the federal level. As a schedule 1 drug Marijuana is difficult to research because grants are restricted.Thankfully, Director Langevin's department is providing $3 million in grants to fund the studies into the benefits of cannabis compounds beside THC. The focus will be to develop and discover therapeutic alternatives to prescription opiods. The three panelists agreed that more ahs to be done by legislators for the full medicinal applications of marijuana to be understood and utilized for the benefit of patients across the country. Congresswoman Barbara Lee stated during the hearing her own anecdotal experience with her mother using a cannabis based pain-relieving lotion to treat her knee pain.